{"ticker": {"uuid": "3eca65e2-c462-41d7-a667-cd39497a4dd8", "symbol": "AVBP", "name": "ArriVent BioPharma, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZEFGVmdfcTdqdG8wbHdhdzA3ZGluM3EzbEtmVjdha01DOUZiS1lLeWdTanpVZzFSUGZVNC1KRkl4anhETTBuUG8wazc2UlJTcTU5NnpvbXV1Zk5HSTZlNWRCWHppay1kVGQ3U2FyLURLT2tJZEI2dno5ank5eVItc2pYQkpEMGRkelB1TUNGQ3oxQ1pfS0lBRklxR2VxSHBpcENwZng4TTUtMl9HMkRtdW00ZEpnNzBGTm4w?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T19:37:07+00:00", "published_display": "15 Jul 2026 19:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42", "summary": "BTIG has reiterated its Buy rating for ArriVent BioPharma (AVBP.US) and maintained its price target of $42. This sustained positive outlook suggests continued confidence in the company's prospects by the investment firm.", "url": "https://www.moomoo.com/news/post/73008021/btig-maintains-arrivent-biopharma-avbpus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-15T19:42:25", "published_display": "15 Jul 2026 19:42", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(AVBP) Volatility Zones as Tactical Triggers", "summary": "This article analyzes Arrivent Biopharma Inc. (NASDAQ: AVBP) using AI models to provide tactical trading triggers. It identifies weak near-term sentiment but strong mid and long-term outlooks, outlining specific entry, target, and stop-loss zones for position, momentum, and risk-", "url": "https://news.stocktradersdaily.com/news_release/12/AVBP_Volatility_Zones_as_Tactical_Triggers_071226095601_1783864561.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T09:40:49", "published_display": "12 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45", "summary": "JonesTrading has reiterated its Buy rating for ArriVent BioPharma (AVBP.US) and maintained its target price at $45. This action signals continued confidence in the company's prospects by the investment firm.", "url": "https://www.moomoo.com/news/post/72523998/jonestrading-maintains-arrivent-biopharma-avbpus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-07T11:40:26", "published_display": "07 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides a comprehensive overview of ArriVent BioPharma, Inc.'s financial disclosures and SEC filings, including annual reports (10-K), quarterly reports (10-Q), and earnings releases (8-K). It details key corporate events, earnings summaries, and pipeline progress from", "url": "https://www.tradingview.com/symbols/BOATS-AVBP/documents/", "source_name": "TradingView", "published_at": "2026-07-01T21:11:00", "published_display": "01 Jul 2026 21:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of ArriVent BioPharma, Inc. \u2013 NASDAQ:AVBP", "summary": "This article provides financial information for ArriVent BioPharma, Inc. (NASDAQ: AVBP), specifically focusing on the number of shareholders. It indicates that the company's market is closed with no trades and lists various data providers for its financial and reference data. The", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-30T23:39:39", "published_display": "30 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ArriVent BioPharma, Inc. \u2013 NASDAQ:AVBP", "summary": "This article focuses on the enterprise value to revenue forward metric for ArriVent BioPharma, Inc. (NASDAQ: AVBP). It highlights the financial data available on TradingView for this specific pharmaceutical company. The content appears to be a financial data point from a larger p", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:40:49", "published_display": "29 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ArriVent BioPharma, Inc. \u2013 NASDAQ:AVBP", "summary": "The article focuses on the price-to-earnings forward metric for ArriVent BioPharma, Inc. (NASDAQ: AVBP). It provides navigation and structural elements typical for a financial data platform, indicating where users can find financials, news, community, and technical analysis for t", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:10:57", "published_display": "28 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ArriVent BioPharma, Inc. \u2013 BOATS:AVBP", "summary": "This page provides financial information for ArriVent BioPharma, Inc. (AVBP) on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the \"Price to book forward\" metric for the company. The content also details various features and services offered by Tradin", "url": "https://www.tradingview.com/symbols/BOATS-AVBP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:10:56", "published_display": "28 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of ArriVent BioPharma, Inc. \u2013 BOATS:AVBP", "summary": "This article focuses on the number of shareholders for ArriVent BioPharma, Inc. (AVBP), referencing data from the Blue Ocean Alternative Trade System (BOATS) via TradingView. The content primarily displays navigation and boilerplate information typical of a financial data platfor", "url": "https://www.tradingview.com/symbols/BOATS-AVBP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-28T19:09:51", "published_display": "28 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ArriVent BioPharma, Inc. \u2013 NASDAQ:AVBP", "summary": "This page from TradingView displays the \"Price to book forward\" financial metric for ArriVent BioPharma, Inc. (NASDAQ:AVBP). It indicates that the market was closed at the time of access with no trades occurring. The content is primarily a data placeholder within a financial plat", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:41:16", "published_display": "28 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ArriVent BioPharma, Inc. \u2013 BOATS:AVBP", "summary": "This article provides financial information for ArriVent BioPharma, Inc. (AVBP) with a focus on its price-to-earnings forward metric. The content highlights the company's financials, news, and market data available through the TradingView platform. It appears to be a financial da", "url": "https://www.tradingview.com/symbols/BOATS-AVBP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:41:16", "published_display": "28 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) Posts Modest Gain at $34.0, Hovers Near Resistance - Price Momentum Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQUjl0VW5NNnlUaHN1WExIR21XZ0x3enp6ak5hTFBENHhRZ2puOUdwTUcxenJiSWR6SFd2eTl5VFBEaHFmaGl4WnVhVkZCMUppTURFZ01sVmpsWjY0SU1ZUmdWNHRDMGlocVYwZmF1TF92U3NURXVVT2EtV1lVdG5IYWg0ZzE5cDVfTXZTMDZYVXJCNHFza2hKWWptemlpb1ZYMHBvZVlMTFYzUjNoMi1pWEw0MVF6QQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVBP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for ArriVent BioPharma, Inc. (AVBP) stock, including a 1-year price target of $43.92 based on 12 analysts. It details current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings information. The an", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:51", "published_display": "26 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma, Inc. Actuals & Estimates (NASDAQ:AVBP)", "summary": "This article provides an overview of ArriVent BioPharma, Inc. (NASDAQ:AVBP), presenting its current stock price, historical performance, and analyst forecasts. It includes key financial metrics like market capitalization, earnings per share, and revenue, alongside details on vola", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:12:41", "published_display": "26 Jun 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) director receives 13,562 stock options at $31.74", "summary": "ArriVent BioPharma director Chris Nolet was granted 13,562 non-qualified stock options with an exercise price of $31.74 per share. These options are set to expire on June 17, 2036, and the underlying shares will vest on June 18, 2027, contingent on his continued service. The tran", "url": "https://www.stocktitan.net/sec-filings/AVBP/form-4-arri-vent-bio-pharma-inc-insider-trading-activity-7eb9483bba30.html", "source_name": "Stock Titan", "published_at": "2026-06-23T06:09:34", "published_display": "23 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD", "summary": "Arrivent Biopharma Inc (AVBP) stock reached a 52-week high of $33.62, currently trading at $33.14. Despite this achievement, InvestingPro analysis suggests the stock is overvalued. The company recently filed for a $250 million at-the-market equity offering, and Cantor Fitzgerald ", "url": "https://ng.investing.com/news/stock-market-news/arrivent-biopharma-inc-stock-hits-52week-high-at-3365-usd-93CH-2568019", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T05:40:04", "published_display": "23 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options at $31.74", "summary": "ArriVent BioPharma, Inc. (AVBP) director John Hohneker was granted 13,562 non-qualified stock options with an exercise price of $31.74 per share. These options, which expire on June 17, 2036, will vest on the first anniversary of the June 18, 2026 grant date, contingent on Hohnek", "url": "https://www.stocktitan.net/sec-filings/AVBP/form-4-arri-vent-bio-pharma-inc-insider-trading-activity-6540bb69784c.html", "source_name": "Stock Titan", "published_at": "2026-06-23T05:40:04", "published_display": "23 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Arrivent Biopharma Inc For: 22 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Arrivent Biopharma Inc pertaining to June 22. It mentions the stock symbol AVBP and its percentage change. The article itself is very brief and acts more as an announcement of the filing rather than an analysis.", "url": "https://ng.investing.com/news/stock-market-news/form-4-arrivent-biopharma-inc-for-22-june-93CH-2569167", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T04:11:20", "published_display": "23 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options", "summary": "ArriVent BioPharma director Kristine Peterson was granted 13,562 non-qualified stock options at an exercise price of $31.74 per share. These options will vest on the first anniversary of the grant date, provided she continues her service, and are set to expire on June 17, 2036. T", "url": "https://www.stocktitan.net/sec-filings/AVBP/form-4-arri-vent-bio-pharma-inc-insider-trading-activity-e61230628445.html", "source_name": "Stock Titan", "published_at": "2026-06-23T02:10:49", "published_display": "23 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) director receives 13,562 stock options grant", "summary": "ArriVent BioPharma (AVBP) director Parsey Merdad was granted 13,562 non-qualified stock options at an exercise price of $31.74 per share, expiring on June 17, 2036. The options vest on the first anniversary of the June 18, 2026, grant date, contingent on Merdad's continued servic", "url": "https://www.stocktitan.net/sec-filings/AVBP/form-4-arri-vent-bio-pharma-inc-insider-trading-activity-7e16eeabf086.html", "source_name": "Stock Titan", "published_at": "2026-06-23T02:10:48", "published_display": "23 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (NASDAQ: AVBP) 2026 meeting backs board, auditor", "summary": "ArriVent BioPharma, Inc. announced the results of its 2026 annual meeting, where stockholders re-elected three Class II directors\u2014James Healy, John Hohneker, and Stuart Lutzker\u2014to serve until the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP as the in", "url": "https://www.stocktitan.net/sec-filings/AVBP/8-k-arri-vent-bio-pharma-inc-reports-material-event-cc68c98ce67b.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:49", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $31.74", "summary": "Truist Financial has initiated coverage on ArriVent BioPharma (AVBP.US) with a Buy rating. The financial firm has also set a target price of $31.74 for the company's stock. This initiation suggests a positive outlook from Truist Financial on ArriVent BioPharma's future performanc", "url": "https://www.moomoo.com/news/post/71826900/truist-financial-initiates-arrivent-biopharma-avbpus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-22T18:39:52", "published_display": "22 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 87, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (Nasdaq:AVBP) - Stock Analysis", "summary": "ArriVent BioPharma (AVBP) is a clinical-stage biopharmaceutical company focused on developing cancer treatments. The company's stock is currently trading significantly below its estimated fair value, with analysts projecting a 37.5% price increase and strong revenue growth. Recen", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avbp/arrivent-biopharma", "source_name": "Simply Wall Street", "published_at": "2026-06-22T05:40:04", "published_display": "22 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(AVBP) Price Dynamics and Execution-Aware Positioning", "summary": "This article provides an AI-driven analysis of Arrivent Biopharma Inc. (NASDAQ: AVBP), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights a lack of resistance above the current price, suggesting upside potential. The analysis also details th", "url": "https://news.stocktradersdaily.com/news_release/16/AVBP_Price_Dynamics_and_Execution-Aware_Positioning_062026073601_1781955361.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T07:36:00", "published_display": "20 Jun 2026 07:36", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrivent Biopharma Inc (AVBP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Arrivent Biopharma Inc (AVBP), detailing analyst ratings, target prices, and future EPS and revenue growth estimates. Based on 13 analysts, the company currently holds a \"Buy\" rating with a target price of 43.917 USD, representing a ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avbp/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T02:39:47", "published_display": "19 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrivent Biopharma Inc (AVBP) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Arrivent Biopharma Inc (AVBP) through TradingKey. It covers key financial metrics like cash and cash equivalents, total assets, liabilities, free cash flow, and operational efficiency. However, the analysis notes that relevant ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avbp/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T01:42:05", "published_display": "19 Jun 2026 01:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrivent Biopharma Inc (AVBP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Arrivent Biopharma Inc (AVBP), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. However, it notes that relevant data for these valuation metrics have not yet been disclosed by the company. The article presents the company", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avbp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T01:39:47", "published_display": "19 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrivent Biopharma Inc (AVBP) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Arrivent Biopharma Inc (AVBP), detailing its volatility, financial risk, and investment risk metrics. It includes data such as Beta vs S&P 500 index, Maximum Drawdown, 240-Day Volatility, and various return and liquidity indicators. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avbp/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-19T00:42:05", "published_display": "19 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) Stock Valuation After Growing Expectations For EGFR Firmonertinib Trials", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPbFlET1R2WnBnQkstSlBfMmU2QUpXeVo5bGJFTjdMZUJzZTdJejJJcE01bWFldV90ZmJGdE9SbTNHRGY2U2I3bVF0ZjYtS1MxSXliWGJJbmNCQU5PVDlHbWI2Y2ptVDZTa21MLXZzaUFyckJIUU9kaXRVVzRMYUZQNC05ZUNQSkdId1lGTUNtX2k3eFpJczcyaTZfWUlwVGtWYkpSMkM0TEhSVjN4X1lKX2FnVmJQMDBPcGZ5aTFQTXFybm95UDZsUmMtdHdJOFI4ckE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQMEJjUUNLOUpTNWN4RjRpeFNoQ0dtVFpLQ2MzeXlwX1Z5ZnQ5a1lFdXBybjRId2RSR3dVVlpITFFSMnA2Vkg3NVNCM3dZUUVjQXFTUXllekRxOWV1YjdiRzQzOExmb2JVbGJFcmRsNUNzYmdBUnE4MGdzT1pwOWMxX2RPd0NkZU5YMDJYQm9tVUtSY3R4Q0pSaFhtZTg2SWNvSWd6YmtyalB0X05Ma2ZjX1RpQUZYN0o4WnM4bG5KYm5aZEJS?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ArriVent BioPharma Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arrivent-biopharma-reports-first-quarter-200100599.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:01:00+00:00", "published_display": "11 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWEloTUZlSnFkeUJoNXBiN2tROF9xUVZLQUVEQ2JxTFUxVUp6bndGT2hGcTJ4aXM4TlNFamhGSUQxZHJOdUVobEM2dmgzdk0zYzVqZHRYWE95eTFzWl9KLWV6cnIxLWZ1bnAtUGdHQnZDazJaSkVyd1JWTG5tN0JyZWl6ME9hUmJZX3ZmMTdTZXVLRnY4WWpNNHNJQ01iRExGT2pqaTlldlNGX0k?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arrivent-announces-ind-clearance-novel-120000284.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T12:00:00+00:00", "published_display": "07 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma: A First Assessment (NASDAQ:AVBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPcGIxMTY0ZktFS2VUMTJuZGZBTGlGemZITGVVbTBOSDJaT1R3SzVjOHBxdkdXZFctWFdRNVhWQXR2bXFQNUgxZHZRSnBuVkNmdjZ6Vm1zT3ZqRHdXS25Ta3hGVFpIVk1TMG9JV01jay1vc19FNjliMXVnelhGa0Y1QzFaN1Y?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNeXREekJVWmFia0hfNUJUN2lIY0pKTXVDV0JzT3hPRWNpWC1ENXh6NjhFQzZYREN3NFU4ZjBHZzVMN3paeXBJLUtyZjhDUkx4akh6NEF4VzV6eFBuSUZPUHpiNnZDQ09LWFFoeUdLdGdJLWU5XzREcFQ3TkM5NlVOaC0zMi1feWFkZm53VThqbXVGN3BBZ3g3bzRWR2lqMWNiRlE?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOWThvRkJONjFaODBsNlp4enhMVWpaYmdXNFdreXcwazlpNmJza1lnNnB1bHc2WE1qNVBNblNkR1laazB0ZzVUeXhERWlUSDdhY2tPdDgyamhRRnQ4QURBTXBGWkktWnFRb3NYRHZsS3NDS1FWRjBqQ18tRmxvTFI0blZqRGMzWHpGU29CX3RhRjMzc0tUQWtKZF9zSGxUbFhsSVA0MFh0V2NjaHFi?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQcHN1S1Y3a1BUU3dSQ3VPV3pXbnM5cXh3V0FrLW15LWwxQi1iTFUyc3BZblY5a1p2N2FTRklwUldlTXlwLWZfWHFrbXBZMTViZkVtUEFWVU9PRGItNTMwbEFQMVN2YU5lQVg0Smd2S2VRbkdMOGlSd1FZQzVkZXZaT0JpcnZkWnlIWFRMb1E1SmpPV3hZdWV0VXJ4TmdMZ2pnbmE4YVdnbXo1Zw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNNHBZdW9IMGdZb1FreDFuVF92UDRYT3J0eFdpWU5Kdzg1eTh6c1VQRDR6UWYxT3Mwdm9VUDhBdEFWLWR0MkdDRFd0Q1VhSTM2WURMdDJ0Qi05azZXUFgyUXJ2dUpSb3JJSUxjcVlQaWdrUTBJWFJISHRRU29VZlFnRmd5R0RCX3NWYjlDc0hTVGJvb2hTRVFIMG5NWk9NaEtlWXlLaWMyaEVSZFVTSzF2UEMzYmo5UnFPTF81MA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZEFGVmdfcTdqdG8wbHdhdzA3ZGluM3EzbEtmVjdha01DOUZiS1lLeWdTanpVZzFSUGZVNC1KRkl4anhETTBuUG8wazc2UlJTcTU5NnpvbXV1Zk5HSTZlNWRCWHppay1kVGQ3U2FyLURLT2tJZEI2dno5ank5eVItc2pYQkpEMGRkelB1TUNGQ3oxQ1pfS0lBRklxR2VxSHBpcENwZng4TTUtMl9HMkRtdW00ZEpnNzBGTm4w?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T19:37:07+00:00", "published_display": "15 Jul 2026 19:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42", "summary": "BTIG has reiterated its Buy rating for ArriVent BioPharma (AVBP.US) and maintained its price target of $42. This sustained positive outlook suggests continued confidence in the company's prospects by the investment firm.", "url": "https://www.moomoo.com/news/post/73008021/btig-maintains-arrivent-biopharma-avbpus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-15T19:42:25", "published_display": "15 Jul 2026 19:42", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(AVBP) Volatility Zones as Tactical Triggers", "summary": "This article analyzes Arrivent Biopharma Inc. (NASDAQ: AVBP) using AI models to provide tactical trading triggers. It identifies weak near-term sentiment but strong mid and long-term outlooks, outlining specific entry, target, and stop-loss zones for position, momentum, and risk-", "url": "https://news.stocktradersdaily.com/news_release/12/AVBP_Volatility_Zones_as_Tactical_Triggers_071226095601_1783864561.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T09:40:49", "published_display": "12 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45", "summary": "JonesTrading has reiterated its Buy rating for ArriVent BioPharma (AVBP.US) and maintained its target price at $45. This action signals continued confidence in the company's prospects by the investment firm.", "url": "https://www.moomoo.com/news/post/72523998/jonestrading-maintains-arrivent-biopharma-avbpus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-07T11:40:26", "published_display": "07 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides a comprehensive overview of ArriVent BioPharma, Inc.'s financial disclosures and SEC filings, including annual reports (10-K), quarterly reports (10-Q), and earnings releases (8-K). It details key corporate events, earnings summaries, and pipeline progress from", "url": "https://www.tradingview.com/symbols/BOATS-AVBP/documents/", "source_name": "TradingView", "published_at": "2026-07-01T21:11:00", "published_display": "01 Jul 2026 21:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of ArriVent BioPharma, Inc. \u2013 NASDAQ:AVBP", "summary": "This article provides financial information for ArriVent BioPharma, Inc. (NASDAQ: AVBP), specifically focusing on the number of shareholders. It indicates that the company's market is closed with no trades and lists various data providers for its financial and reference data. The", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-30T23:39:39", "published_display": "30 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ArriVent BioPharma, Inc. \u2013 NASDAQ:AVBP", "summary": "This article focuses on the enterprise value to revenue forward metric for ArriVent BioPharma, Inc. (NASDAQ: AVBP). It highlights the financial data available on TradingView for this specific pharmaceutical company. The content appears to be a financial data point from a larger p", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:40:49", "published_display": "29 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ArriVent BioPharma, Inc. \u2013 NASDAQ:AVBP", "summary": "The article focuses on the price-to-earnings forward metric for ArriVent BioPharma, Inc. (NASDAQ: AVBP). It provides navigation and structural elements typical for a financial data platform, indicating where users can find financials, news, community, and technical analysis for t", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:10:57", "published_display": "28 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ArriVent BioPharma, Inc. \u2013 BOATS:AVBP", "summary": "This page provides financial information for ArriVent BioPharma, Inc. (AVBP) on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the \"Price to book forward\" metric for the company. The content also details various features and services offered by Tradin", "url": "https://www.tradingview.com/symbols/BOATS-AVBP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:10:56", "published_display": "28 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of ArriVent BioPharma, Inc. \u2013 BOATS:AVBP", "summary": "This article focuses on the number of shareholders for ArriVent BioPharma, Inc. (AVBP), referencing data from the Blue Ocean Alternative Trade System (BOATS) via TradingView. The content primarily displays navigation and boilerplate information typical of a financial data platfor", "url": "https://www.tradingview.com/symbols/BOATS-AVBP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-28T19:09:51", "published_display": "28 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ArriVent BioPharma, Inc. \u2013 NASDAQ:AVBP", "summary": "This page from TradingView displays the \"Price to book forward\" financial metric for ArriVent BioPharma, Inc. (NASDAQ:AVBP). It indicates that the market was closed at the time of access with no trades occurring. The content is primarily a data placeholder within a financial plat", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:41:16", "published_display": "28 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ArriVent BioPharma, Inc. \u2013 BOATS:AVBP", "summary": "This article provides financial information for ArriVent BioPharma, Inc. (AVBP) with a focus on its price-to-earnings forward metric. The content highlights the company's financials, news, and market data available through the TradingView platform. It appears to be a financial da", "url": "https://www.tradingview.com/symbols/BOATS-AVBP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:41:16", "published_display": "28 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) Posts Modest Gain at $34.0, Hovers Near Resistance - Price Momentum Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQUjl0VW5NNnlUaHN1WExIR21XZ0x3enp6ak5hTFBENHhRZ2puOUdwTUcxenJiSWR6SFd2eTl5VFBEaHFmaGl4WnVhVkZCMUppTURFZ01sVmpsWjY0SU1ZUmdWNHRDMGlocVYwZmF1TF92U3NURXVVT2EtV1lVdG5IYWg0ZzE5cDVfTXZTMDZYVXJCNHFza2hKWWptemlpb1ZYMHBvZVlMTFYzUjNoMi1pWEw0MVF6QQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVBP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for ArriVent BioPharma, Inc. (AVBP) stock, including a 1-year price target of $43.92 based on 12 analysts. It details current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings information. The an", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:51", "published_display": "26 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma, Inc. Actuals & Estimates (NASDAQ:AVBP)", "summary": "This article provides an overview of ArriVent BioPharma, Inc. (NASDAQ:AVBP), presenting its current stock price, historical performance, and analyst forecasts. It includes key financial metrics like market capitalization, earnings per share, and revenue, alongside details on vola", "url": "https://www.tradingview.com/symbols/NASDAQ-AVBP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:12:41", "published_display": "26 Jun 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) director receives 13,562 stock options at $31.74", "summary": "ArriVent BioPharma director Chris Nolet was granted 13,562 non-qualified stock options with an exercise price of $31.74 per share. These options are set to expire on June 17, 2036, and the underlying shares will vest on June 18, 2027, contingent on his continued service. The tran", "url": "https://www.stocktitan.net/sec-filings/AVBP/form-4-arri-vent-bio-pharma-inc-insider-trading-activity-7eb9483bba30.html", "source_name": "Stock Titan", "published_at": "2026-06-23T06:09:34", "published_display": "23 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD", "summary": "Arrivent Biopharma Inc (AVBP) stock reached a 52-week high of $33.62, currently trading at $33.14. Despite this achievement, InvestingPro analysis suggests the stock is overvalued. The company recently filed for a $250 million at-the-market equity offering, and Cantor Fitzgerald ", "url": "https://ng.investing.com/news/stock-market-news/arrivent-biopharma-inc-stock-hits-52week-high-at-3365-usd-93CH-2568019", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T05:40:04", "published_display": "23 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options at $31.74", "summary": "ArriVent BioPharma, Inc. (AVBP) director John Hohneker was granted 13,562 non-qualified stock options with an exercise price of $31.74 per share. These options, which expire on June 17, 2036, will vest on the first anniversary of the June 18, 2026 grant date, contingent on Hohnek", "url": "https://www.stocktitan.net/sec-filings/AVBP/form-4-arri-vent-bio-pharma-inc-insider-trading-activity-6540bb69784c.html", "source_name": "Stock Titan", "published_at": "2026-06-23T05:40:04", "published_display": "23 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Arrivent Biopharma Inc For: 22 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Arrivent Biopharma Inc pertaining to June 22. It mentions the stock symbol AVBP and its percentage change. The article itself is very brief and acts more as an announcement of the filing rather than an analysis.", "url": "https://ng.investing.com/news/stock-market-news/form-4-arrivent-biopharma-inc-for-22-june-93CH-2569167", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T04:11:20", "published_display": "23 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options", "summary": "ArriVent BioPharma director Kristine Peterson was granted 13,562 non-qualified stock options at an exercise price of $31.74 per share. These options will vest on the first anniversary of the grant date, provided she continues her service, and are set to expire on June 17, 2036. T", "url": "https://www.stocktitan.net/sec-filings/AVBP/form-4-arri-vent-bio-pharma-inc-insider-trading-activity-e61230628445.html", "source_name": "Stock Titan", "published_at": "2026-06-23T02:10:49", "published_display": "23 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) director receives 13,562 stock options grant", "summary": "ArriVent BioPharma (AVBP) director Parsey Merdad was granted 13,562 non-qualified stock options at an exercise price of $31.74 per share, expiring on June 17, 2036. The options vest on the first anniversary of the June 18, 2026, grant date, contingent on Merdad's continued servic", "url": "https://www.stocktitan.net/sec-filings/AVBP/form-4-arri-vent-bio-pharma-inc-insider-trading-activity-7e16eeabf086.html", "source_name": "Stock Titan", "published_at": "2026-06-23T02:10:48", "published_display": "23 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (NASDAQ: AVBP) 2026 meeting backs board, auditor", "summary": "ArriVent BioPharma, Inc. announced the results of its 2026 annual meeting, where stockholders re-elected three Class II directors\u2014James Healy, John Hohneker, and Stuart Lutzker\u2014to serve until the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP as the in", "url": "https://www.stocktitan.net/sec-filings/AVBP/8-k-arri-vent-bio-pharma-inc-reports-material-event-cc68c98ce67b.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:49", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $31.74", "summary": "Truist Financial has initiated coverage on ArriVent BioPharma (AVBP.US) with a Buy rating. The financial firm has also set a target price of $31.74 for the company's stock. This initiation suggests a positive outlook from Truist Financial on ArriVent BioPharma's future performanc", "url": "https://www.moomoo.com/news/post/71826900/truist-financial-initiates-arrivent-biopharma-avbpus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-22T18:39:52", "published_display": "22 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 87, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (Nasdaq:AVBP) - Stock Analysis", "summary": "ArriVent BioPharma (AVBP) is a clinical-stage biopharmaceutical company focused on developing cancer treatments. The company's stock is currently trading significantly below its estimated fair value, with analysts projecting a 37.5% price increase and strong revenue growth. Recen", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avbp/arrivent-biopharma", "source_name": "Simply Wall Street", "published_at": "2026-06-22T05:40:04", "published_display": "22 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(AVBP) Price Dynamics and Execution-Aware Positioning", "summary": "This article provides an AI-driven analysis of Arrivent Biopharma Inc. (NASDAQ: AVBP), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights a lack of resistance above the current price, suggesting upside potential. The analysis also details th", "url": "https://news.stocktradersdaily.com/news_release/16/AVBP_Price_Dynamics_and_Execution-Aware_Positioning_062026073601_1781955361.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T07:36:00", "published_display": "20 Jun 2026 07:36", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrivent Biopharma Inc (AVBP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Arrivent Biopharma Inc (AVBP), detailing analyst ratings, target prices, and future EPS and revenue growth estimates. Based on 13 analysts, the company currently holds a \"Buy\" rating with a target price of 43.917 USD, representing a ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avbp/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T02:39:47", "published_display": "19 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrivent Biopharma Inc (AVBP) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Arrivent Biopharma Inc (AVBP) through TradingKey. It covers key financial metrics like cash and cash equivalents, total assets, liabilities, free cash flow, and operational efficiency. However, the analysis notes that relevant ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avbp/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T01:42:05", "published_display": "19 Jun 2026 01:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrivent Biopharma Inc (AVBP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Arrivent Biopharma Inc (AVBP), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. However, it notes that relevant data for these valuation metrics have not yet been disclosed by the company. The article presents the company", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avbp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T01:39:47", "published_display": "19 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrivent Biopharma Inc (AVBP) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Arrivent Biopharma Inc (AVBP), detailing its volatility, financial risk, and investment risk metrics. It includes data such as Beta vs S&P 500 index, Maximum Drawdown, 240-Day Volatility, and various return and liquidity indicators. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-avbp/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-19T00:42:05", "published_display": "19 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma (AVBP) Stock Valuation After Growing Expectations For EGFR Firmonertinib Trials", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPbFlET1R2WnBnQkstSlBfMmU2QUpXeVo5bGJFTjdMZUJzZTdJejJJcE01bWFldV90ZmJGdE9SbTNHRGY2U2I3bVF0ZjYtS1MxSXliWGJJbmNCQU5PVDlHbWI2Y2ptVDZTa21MLXZzaUFyckJIUU9kaXRVVzRMYUZQNC05ZUNQSkdId1lGTUNtX2k3eFpJczcyaTZfWUlwVGtWYkpSMkM0TEhSVjN4X1lKX2FnVmJQMDBPcGZ5aTFQTXFybm95UDZsUmMtdHdJOFI4ckE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQMEJjUUNLOUpTNWN4RjRpeFNoQ0dtVFpLQ2MzeXlwX1Z5ZnQ5a1lFdXBybjRId2RSR3dVVlpITFFSMnA2Vkg3NVNCM3dZUUVjQXFTUXllekRxOWV1YjdiRzQzOExmb2JVbGJFcmRsNUNzYmdBUnE4MGdzT1pwOWMxX2RPd0NkZU5YMDJYQm9tVUtSY3R4Q0pSaFhtZTg2SWNvSWd6YmtyalB0X05Ma2ZjX1RpQUZYN0o4WnM4bG5KYm5aZEJS?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arrivent-biopharma-reports-first-quarter-200100599.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:01:00+00:00", "published_display": "11 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWEloTUZlSnFkeUJoNXBiN2tROF9xUVZLQUVEQ2JxTFUxVUp6bndGT2hGcTJ4aXM4TlNFamhGSUQxZHJOdUVobEM2dmgzdk0zYzVqZHRYWE95eTFzWl9KLWV6cnIxLWZ1bnAtUGdHQnZDazJaSkVyd1JWTG5tN0JyZWl6ME9hUmJZX3ZmMTdTZXVLRnY4WWpNNHNJQ01iRExGT2pqaTlldlNGX0k?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arrivent-announces-ind-clearance-novel-120000284.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T12:00:00+00:00", "published_display": "07 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma: A First Assessment (NASDAQ:AVBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPcGIxMTY0ZktFS2VUMTJuZGZBTGlGemZITGVVbTBOSDJaT1R3SzVjOHBxdkdXZFctWFdRNVhWQXR2bXFQNUgxZHZRSnBuVkNmdjZ6Vm1zT3ZqRHdXS25Ta3hGVFpIVk1TMG9JV01jay1vc19FNjliMXVnelhGa0Y1QzFaN1Y?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNeXREekJVWmFia0hfNUJUN2lIY0pKTXVDV0JzT3hPRWNpWC1ENXh6NjhFQzZYREN3NFU4ZjBHZzVMN3paeXBJLUtyZjhDUkx4akh6NEF4VzV6eFBuSUZPUHpiNnZDQ09LWFFoeUdLdGdJLWU5XzREcFQ3TkM5NlVOaC0zMi1feWFkZm53VThqbXVGN3BBZ3g3bzRWR2lqMWNiRlE?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOWThvRkJONjFaODBsNlp4enhMVWpaYmdXNFdreXcwazlpNmJza1lnNnB1bHc2WE1qNVBNblNkR1laazB0ZzVUeXhERWlUSDdhY2tPdDgyamhRRnQ4QURBTXBGWkktWnFRb3NYRHZsS3NDS1FWRjBqQ18tRmxvTFI0blZqRGMzWHpGU29CX3RhRjMzc0tUQWtKZF9zSGxUbFhsSVA0MFh0V2NjaHFi?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQcHN1S1Y3a1BUU3dSQ3VPV3pXbnM5cXh3V0FrLW15LWwxQi1iTFUyc3BZblY5a1p2N2FTRklwUldlTXlwLWZfWHFrbXBZMTViZkVtUEFWVU9PRGItNTMwbEFQMVN2YU5lQVg0Smd2S2VRbkdMOGlSd1FZQzVkZXZaT0JpcnZkWnlIWFRMb1E1SmpPV3hZdWV0VXJ4TmdMZ2pnbmE4YVdnbXo1Zw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNNHBZdW9IMGdZb1FreDFuVF92UDRYT3J0eFdpWU5Kdzg1eTh6c1VQRDR6UWYxT3Mwdm9VUDhBdEFWLWR0MkdDRFd0Q1VhSTM2WURMdDJ0Qi05azZXUFgyUXJ2dUpSb3JJSUxjcVlQaWdrUTBJWFJISHRRU29VZlFnRmd5R0RCX3NWYjlDc0hTVGJvb2hTRVFIMG5NWk9NaEtlWXlLaWMyaEVSZFVTSzF2UEMzYmo5UnFPTF81MA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 67, "sentiment_summary": {"positive": 21, "negative": 2, "neutral": 44, "score": 56, "total": 67, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 20.8, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 13.0, "count": 25}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 33.19, "latest_week": "2026-07-17", "one_week_move": -1.5, "four_week_move": 4.6, "twelve_week_move": 9.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.506235, "market_dynamics_buy_signal": false, "relative_strength": 26.743022, "fair_value_gap": 44.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.1153, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.5% over one week, +4.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "TradingView", "count": 12}, {"label": "Stock Titan", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Seeking Alpha", "count": 3}, {"label": "Stock Traders Daily", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 59}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 25}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "59", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "7", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.5% over one week, +4.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42"}], "updated_at": "2026-07-21T22:33:20.365408+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}